Comparative Pharmacology
Head-to-head clinical analysis: TRI LO MILI versus TRIPHASIL 21.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRI LO MILI versus TRIPHASIL 21.
TRI-LO-MILI vs TRIPHASIL-21
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on the hypothalamic-pituitary axis; norgestimate binds to progesterone receptors, inhibiting ovulation and altering cervical mucus and endometrial receptivity.
Combination of ethinyl estradiol and levonorgestrel suppresses gonadotropin release, inhibiting ovulation; alters cervical mucus to impair sperm penetration and endometrial receptivity.
One tablet orally once daily for 21 days, followed by 7 days of placebo.
One tablet orally daily for 21 days, followed by 7 drug-free days. Each tablet contains levonorgestrel 0.05 mg and ethinyl estradiol 0.03 mg (days 1-6), levonorgestrel 0.075 mg and ethinyl estradiol 0.04 mg (days 7-11), and levonorgestrel 0.125 mg and ethinyl estradiol 0.03 mg (days 12-21).
None Documented
None Documented
Terminal elimination half-life: 20-24 hours; allows once-daily dosing for contraceptive efficacy.
Levonorgestrel: 10-45 hours (terminal, biphasic); ethinyl estradiol: 10-27 hours (terminal, triphasic). Clinical context: Steady state reached after 7-14 days with daily dosing.
Renal: approximately 50% as metabolites; biliary/fecal: approximately 40% as metabolites; 10% unchanged in urine.
Renal: 30-50% (ethinyl estradiol and levonorgestrel metabolites as glucuronide and sulfate conjugates). Fecal: 30-50% (biliary excretion of unconjugated metabolites). Unchanged drug: negligible.
Category C
Category C
Oral Contraceptive
Oral Contraceptive